STAT3与帕金森病发病机制的研究进展

doi:10.16352/j.issn.1001-6325.2022.12.1935

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (12): 1935-1938.doi: 10.16352/j.issn.1001-6325.2022.12.1935

STAT3与帕金森病发病机制的研究进展

吴长宝¹, 郝延磊^2*

1.济宁医学院临床医学院,山东济宁 272029;
2.济宁医学院附属医院神经内科,山东济宁 272029

收稿日期:2022-06-10 修回日期:2022-09-28 出版日期:2022-12-05 发布日期:2022-11-23
通讯作者: ^* yanleihao301@live.com
基金资助:
国家自然科学基金(81771360); 济宁市重点研发计划项目(2021YXNS101)

Research progress on STAT3 and pathogenesis of Parkinson's disease

WU Chang-bao¹, HAO Yan-lei^2*

1. Medical College of Jining Medical University, Jining 272029;
2. Department of Neurology, Affiliated Hospital of Jining Medical University, Jining 272029, China

Received:2022-06-10 Revised:2022-09-28 Online:2022-12-05 Published:2022-11-23
Contact: ^* yanleihao301@live.com

摘要/Abstract

摘要： 帕金森病(PD)是一种慢性进行性神经退行性疾病。信号传导与转录激活因子3(STAT3)在氧化应激、神经炎性反应、α-突触核蛋白异常聚集、线粒体功能障碍和铁死亡中参与PD的发生和发展,有望成为新的治疗靶点,为PD的治疗提供新的研究思路。

关键词: STAT3转录因子, 帕金森病, 发病机制

Abstract: Parkinson's disease (PD) is a chronic progressive neurodegenerative disease. Signal transducer and activator of transcription 3 (STAT3) is involved in the development and progression of PD, oxidative stress, neuro-inflammatory response, abnormal α-synuclein aggregation, mitochondrial dysfunction and iron death, so they are expected to be a new therapeutic targets and provide new research ideas for the treatment of PD.

Key words: STAT3 transcription factor, Parkinson's disease, pathogenesis

中图分类号:

吴长宝, 郝延磊. STAT3与帕金森病发病机制的研究进展[J]. 基础医学与临床, 2022, 42(12): 1935-1938.

WU Chang-bao, HAO Yan-lei. Research progress on STAT3 and pathogenesis of Parkinson's disease[J]. Basic & Clinical Medicine, 2022, 42(12): 1935-1938.

参考文献

[1]Tran KKN, Wong VHY, Lim JKH, et al. Characterization of retinal function and structure in the MPTP murine model of Parkinson's disease[J].Sci Rep, 2022,12:7610-7620.
[2]Dong J, Cheng XD, Zhang WD, et al. Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation[J].J Med Chem,2021,64:8884-8915.
[3]Qin J, Shen X, Zhang J, et al. Allosteric inhibitors of the STAT3 signaling pathway[J]. Eur J Med Chem, 2020,190:112-122.
[4]Shiah JV, Grandis JR, Johnson DE. Targeting STAT3 with proteolysis targeting chimeras and next-generation antisense oligonucleotides[J].Mol Cancer Ther, 2021,20:219-228.
[5]Liu L, Wang J, Wang H. Hydrogen sulfide alleviates oxidative stress injury and reduces apoptosis induced by MPP⁺ in Parkinson's disease cell model[J].Mol Cell Biochem, 2020,472:231-240.
[6]Xu Z,Yang D,Huang X, et al. Astragaloside Ⅳ protects 6-hydroxydopamine-induced SH-SY5Y cell model of Parkinson's disease via activating the JAK2/STAT3 pathway[J].Front Neurosci,2021,15:631501-631510.
[7]He D,Chen S,Xiao Z, et al. Bisdemethoxycurcumin exerts a cell-protective effect via JAK2/STAT3 signaling in a rotenone-induced Parkinson's disease model in vitro[J].Folia Histochem Cytobiol,2020,58:127-134.
[8]Wang Q, Liu Y. Cryptotanshinone ameliorates MPP⁺-induced oxidative stress and apoptosis of SH-SY5Y neuroblastoma cells: the role of STAT3 in Parkinson's disease[J]. Metab Brain Dis, 2022,37:1477-1485.
[9]Pajares MI, Rojo A, Manda G, et al. Inflammation in Parkinson's disease: mechanisms and therapeutic implications[J].Cells,2020,9:1687-1718.
[10]Wang X, Li X, Zuo X, et al. Photobiomodulation inhibits the activation of neurotoxic microglia and astrocytes by inhibiting Lcn2/JAK2-STAT3 crosstalk after spinal cord injury in male rats[J].J Neuroinflammation, 2021,18:256-275.
[11]Cong L, Lei MY, Liu ZQ, et al. Resveratrol attenuates manganese-induced oxidative stress and neuroinflammation through SIRT1 signaling in mice[J]. Food Chem Toxicol, 2021,153:112283-112295.
[12]Wang X,Liu Z,Wang F.MicroRNA-93 blocks signal transducers and activator of transcription 3 to reduce neuronal damage in Parkinson's dsease[J].Neurochem Res,2021,46:1859-1868.
[13]Hashioka S, McGeer EG, et al. Interferon-γ-induced neurotoxicity of human astrocytes[J]. CNS Neurol Disord Drug Targets,2015,14:251-256.
[14]Choi JY, Yun J, Hwang CJ, et al. (E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl) phenol ameliorates MPTP-induced dopaminergic neurodegeneration by inhibiting the STAT3 pathway[J].Int J Mol Sci,2019,20:2632-2647.
[15]Srinivasan E, Chandrasekhar G, Chandrasekar P, et al. Alpha-synuclein aggregation in Parkinson's disease[J].Front Med,2021:736978.
[16]Li Y, Xia Y, Yin S, et al. Targeting microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 inflammasome axis in Parkinson's dsease[J].Front Immunol, 2021,12:719807-719822.
[17]Zhang J, Zhou DW, Zhang Z, et al.miR-let-7a suppres-ses α-Synuclein-induc-ed microglia inflammation through targeting STAT3 in Parkinson's disease[J].Biochem Biophys Res Commun,2019,519:740-746.
[18]Liu J, Shi M, Hong Z, et al. Identification of ciliary neurotrophic factor receptor alpha as a mediator of neurotoxi-city induced by alpha-synuclein[J]. Proteomics,2010,10:2138-2150.
[19]Iravanpour F, Dargahi L, Rezaei M, et al. Intranasal insulin improves mitochondrial function and attenuates motor deficits in a rat 6-OHDA model of Parkinson's disease[J].CNS Neurosci Ther, 2021,27:308-319.
[20]Zeng L, Li A, Zhang Z, et al. Ropivacaine induces cell cycle arrest in the G0/G1 Phase and apoptosis of PC12 cells via inhibiting mitochondrial STAT3 translocation[J].Inflammation,2021,44:2362-2376.
[21]Qian ZM, Ke Y. Hepcidin and its therapeutic potential in neurodegenerative disorders[J].Med Res Rev, 2020,40:633-653.
[22]Billesbølle CB, Azumaya CM, Kretsch RC, et al. Struc-ture of hepcidin-bound ferroportin reveals iron homeostatic mechanisms[J].Nature, 2020,586:807-811.
[23]Angelova PR, Esteras N, Abramov AY. Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention[J].Med Res Rev, 2021,41:770-784.
[24]Deng H, Liu S, Pan D, et al. Myricetin reduces cytotoxicity by suppressing hepcidin expression in MES23.5 cells[J].Neural Regen Res,2021,16:1105-1110.

STAT3与帕金森病发病机制的研究进展

Research progress on STAT3 and pathogenesis of Parkinson's disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	于曼殊, 赵晓敏, 邱明月, 刘春冉, 那日苏. 牙源性干细胞治疗帕金森病的研究进展[J]. 基础医学与临床, 2024, 44(9): 1298-1302.
[2]	苏凌峰, 王虎霞, 王延峰, 宋张骏. 慢性压力对乳腺癌发展的影响[J]. 基础医学与临床, 2024, 44(9): 1303-1307.
[3]	彭晴怡, 许岭翎. 1型糖尿病诱发肌少症的研究进展[J]. 基础医学与临床, 2024, 44(8): 1189-1193.
[4]	张雅慧, 白琼. 低氧诱导因子-1α在糖尿病肾病中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(1): 114-118.
[5]	任鹏, 陈雅丽, 张娴文. 帕金森病嗅觉障碍的研究进展[J]. 基础医学与临床, 2023, 43(6): 994-997.
[6]	岳静静, 伍超, 高歌, 鲁玲玲. α-突触核蛋白/A53T突变体损伤SH-SY5Y细胞的MAM并导致线粒体结构异常及自噬[J]. 基础医学与临床, 2023, 43(2): 219-224.
[7]	蒋琪, 杨柳, 和娇娇, 李维辛. 脂毒性在肌少症发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(12): 1886-1890.
[8]	沈露茜, 徐学静, 叶逸繁, 陈卓, 陈兰, 申钰琪, 李红智. 导入酵母NDI1基因减少鱼藤酮诱导的分化型帕金森病细胞模型的损伤[J]. 基础医学与临床, 2023, 43(10): 1491-1497.
[9]	孙慧, 陈思宇. 微生物相关肿瘤的发病机制及其治疗的研究进展[J]. 基础医学与临床, 2023, 43(1): 178-182.
[10]	林柏柏, 钱风华, 钱义明, 赵雷, 孙旗, 褚梦瑶, 沈梦雯. 脓毒症并发毛细血管渗漏综合征的研究进展[J]. 基础医学与临床, 2022, 42(7): 1144-1147.
[11]	赵肖灵, 何润之, 孙玉姣, 张小冲, 杨林芳, 王瑞, 程芳. 活动期白癜风患者血清γ干扰素含量升高[J]. 基础医学与临床, 2022, 42(7): 1067-1070.
[12]	左赋兴, 苑青, 蔡洪庆, 韩睿钦, 万经海. 新型微量注射装置在建立帕金森病模型小鼠中的应用[J]. 基础医学与临床, 2022, 42(7): 1031-1034.
[13]	王行行, 王导新. NETs与急性呼吸窘迫综合征的研究进展[J]. 基础医学与临床, 2021, 41(7): 1047-1051.
[14]	马利芳, 梁建庆, 何建成, 孙雪, 梁鹏. 谷氨酸转运体在帕金森病发病机制中作用的研究进展[J]. 基础医学与临床, 2021, 41(12): 1813-1817.
[15]	邢靖松, 克甜甜, 张琳, 梁东, 张桐, 高尚锋. Spinophilin在神经系统疾病中的研究进展[J]. 基础医学与临床, 2021, 41(10): 1507-1509.